New Paradigm Capital Management LLC Purchases Shares of 4,400 Eli Lilly and Company $LLY

New Paradigm Capital Management LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,400 shares of the company’s stock, valued at approximately $5,277,000. Eli Lilly and Company makes up approximately 11.3% of New Paradigm Capital Management LLC’s portfolio, making the stock its 3rd biggest holding.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Investment Research Partners LLC lifted its holdings in Eli Lilly and Company by 11.7% during the 2nd quarter. Investment Research Partners LLC now owns 1,847 shares of the company’s stock worth $2,215,000 after buying an additional 194 shares during the last quarter. Steinberganna Wealth Management increased its holdings in shares of Eli Lilly and Company by 2.2% in the 2nd quarter. Steinberganna Wealth Management now owns 959 shares of the company’s stock valued at $1,150,000 after acquiring an additional 21 shares during the last quarter. 71 West Capital Partners raised its position in shares of Eli Lilly and Company by 49.4% during the 2nd quarter. 71 West Capital Partners now owns 5,922 shares of the company’s stock worth $7,103,000 after acquiring an additional 1,959 shares in the last quarter. Cape ANN Savings Bank lifted its stake in Eli Lilly and Company by 9.8% during the second quarter. Cape ANN Savings Bank now owns 760 shares of the company’s stock worth $912,000 after purchasing an additional 68 shares during the last quarter. Finally, Founders Financial Alliance LLC boosted its holdings in Eli Lilly and Company by 13.8% in the second quarter. Founders Financial Alliance LLC now owns 1,993 shares of the company’s stock valued at $2,391,000 after purchasing an additional 242 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide results support higher guidance. Favorable trial results for retatrutide, Lilly’s next-generation obesity and diabetes candidate, reportedly prompted the company to lift its guidance. The update strengthens expectations that Lilly can extend its GLP-1 growth beyond Mounjaro and Zepbound. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
• Positive Sentiment: New OmniAb collaboration expands Lilly’s discovery pipeline. Lilly signed a global collaboration and licensing agreement with OmniAb for an ion-channel drug-discovery program. The deal, which could provide OmniAb with up to $370 million in milestones, gives Lilly access to additional technology and potential future medicines while reinforcing its investment in pipeline development. OmniAb Announces Global Collaboration and License Agreement
• Positive Sentiment: Recent growth catalysts remain intact. Commentary highlights Lilly’s robust second-quarter performance, approximately 48% year-over-year revenue growth, UK regulatory approval, a Medicare access program and continuing GLP-1 demand. Analysts also point to strong momentum and a broad pipeline as reasons for long-term optimism. Eli Lilly’s Growth Story Keeps Adding Chapters
• Neutral Sentiment: Valuation remains debated. A discounted-cash-flow analysis suggests potential upside, but Lilly’s five-year total return of more than 360% and elevated trading multiples mean substantial future growth is already reflected in the stock. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?
• Negative Sentiment: Competition and pricing risks remain. Analysts view strong GLP-1 momentum favorably but caution that Lilly’s valuation is demanding and competition, pricing pressure and future patent headwinds could limit additional upside. LLY Up After Robust Q2 Results

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Barclays raised their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Trading Up 0.4%

NYSE:LLY opened at $1,184.44 on Tuesday. Eli Lilly and Company has a 52-week low of $685.15 and a 52-week high of $1,249.45. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a fifty day simple moving average of $1,171.52 and a 200-day simple moving average of $1,053.72. The company has a market capitalization of $1.11 trillion, a PE ratio of 39.75, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.